Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scios Overhauls Natrecor Physician Promotion

This article was originally published in The Pink Sheet Daily

Executive Summary

The Johnson & Johnson subsidiary's program for its congestive heart failure agent includes sales force training and new promotional materials that reflect expert panel recommendations on nesiritide use.

You may also be interested in...



J&J’s Natrecor Out Of Medicare For Chronic Heart Failure

CMS’ final national coverage determination does not change contractor discretion to cover other off-label uses.

J&J’s Natrecor Out Of Medicare For Chronic Heart Failure

CMS’ final national coverage determination does not change contractor discretion to cover other off-label uses.

J&J Natrecor "Dear Doctor" Letter Discusses Appropriate Use In Heart Failure

Scios uses "Dear Doctor" letter to alert physicians to independent panel's recommendations for appropriate and inappropriate uses of nesiritide. The letter recommends use of Natrecor only in a clinical setting where blood pressure can be closely monitored.

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel